echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clinical Lung Cancer: Efficacy of Durvalumab maintenance therapy after concurrent radiotherapy and chemotherapy in elderly patients with unresectable stage III non-small cell lung cancer (NSCLC): Post-mortem analysis of the PACIFIC study

    Clinical Lung Cancer: Efficacy of Durvalumab maintenance therapy after concurrent radiotherapy and chemotherapy in elderly patients with unresectable stage III non-small cell lung cancer (NSCLC): Post-mortem analysis of the PACIFIC study

    • Last Update: 2021-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    PACIFIC is a placebo-controlled phase III clinical trial.


    PACIFIC is a placebo-controlled phase III clinical trial.


    A total of 713 patients were randomized; 158/713 (22.


    A total of 713 patients were randomized; 158/713 (22.


    The PFS analysis was performed for the first time on February 13, 2017.



     PFS

    The first OS analysis was performed on March 22, 2018.


    The first OS analysis was performed on March 22, 2018.



    OS

    Regardless of age, the ORR of the durvalumab group was higher than that of the placebo group


    Regardless of age, the ORR of the durvalumab group was higher than that of the placebo group



    Efficacy evaluation

    Consistent with the ITT population, the durvalumab group received a lower proportion of subsequent anti-tumor treatments, patients ≥70 years old (durvalumab, 36.


    Consistent with the ITT population, the durvalumab group received a lower proportion of subsequent anti-tumor treatments, patients ≥70 years old (durvalumab, 36.


    Patients in the durvalumab group ≥70 years of age experienced a higher proportion of grade 3/4 adverse events (durvalumab, 41.


    In summary, the elderly patients with unresectable stage III non-small cell lung cancer (NSCLC) still benefit from Durvalumab maintenance treatment after concurrent radiotherapy and chemotherapy, and the toxicity is controllable and tolerable


    Original source:

    Mark A.
    Socinski, Mustafa Ozgüro˘ glu, Augusto Villegas, et al.
    Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients with Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
    Clinical Lung Cancer.
    2021.
    DOI: https:// doi.
    org/10.
    1016/j.
    cllc.
    2021.
    05.
    009.

    Mark A.
    Socinski, Mustafa Ozgüro˘ glu, Augusto Villegas, et al.
    Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients with Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
    Clinical Lung Cancer.
    2021.
    DOI: https:// doi.
    org/10.
    1016/j.
    cllc.
    2021.
    05.
    009.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.